Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Y2k_fan who wrote (1221)	6/15/1998 11:57:00 AM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

The OmniCath currently in phase II testing may have some significant advantages compared to other atherectomy devices in delaying restenosis. Restenosis for those who may not know is the reoccurrence of cholesterol buildup in a blood vessel after it has been cleared by angioplasty. This unfortunate occurrence happens after balloon angioplasty, atherectomy proceedures and even after the placement of stents. americanbiomed.com As Reesed points out silicone is an inert material that has some distinct advantages over latex or PVC. One of those advantages might just be the use of drug delivery to help prevent or further delay restenosis after the narrowing of an artery is treated by one of the procedures mentioned above. messages.yahoo.com@m2.yahoo.com americanbiomed.com Now the OmniCath may definitely delay restenosis especially when compared to traditional balloon angioplasty. I have previously posted on it's advantages. americanbiomed.com How about some possible uses for American BioMed's Everto-Cath? Drug delivery is the main reason for the design of this catheter within a catheter design. The company may be working on a design that will place stents as well. But as we know even after the placement of a stent some restenosis will occur. The Everto-Cath could be designed to deliver the stent along with an additional agent(drugs) to help prevent restenosis. americanbiomed.com I have done a little reading on the subject and have found that radioisotopes are being tested by some companies. Antioxidant drugs are also being studied. We know restenosis is a problem that will not be going away. What Reesed and his friend have pointed out is that American BioMed and it's 100% silicone Catheter designs could ultimately hold significant potential in delivering agents that will help either slow or significantly prevent this occurrence. Thanks Reesed! Regards, Jeff